The Latest Breaking News from BSX

Boston Scientific has outperformed the Nasdaq Composite over the past year, and analysts remain bullish on the stock’s prospects.

MedTech’s bright future is fueled by rapid tech advancements and increasing demand for medical devices, implants, and precision treatments, driven by an aging population and rising global disease rates. Given this backdrop, adding strong MedTech stocks like Boston Scientific (BSX), Stryker (SYK), and Abbott (ABT) to one’s portfolio could be…

Coupled with the macroeconomic headwinds, the U.S. debt default crisis and consequent recessionary fears have triggered market volatility. Against this backdrop, quality growth stocks Boston Scientific (BSX), Cardinal Health (CAH), Cidara Therapeutics (CDTX), and Geospace Technologies (GEOS) could be solid buys now. Read on….

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.66% on an annualized basis producing an average annual return of 20.68%. Currently, Boston Scientific has a market capitalization of $54.31 billion.

Boston Scientific Corporation (NYSE:BSX) has agreed to purchase Synergy Innovation Co Ltd's majority stake (~64%) of M.I.Tech Co Ltd, a publicly-traded Korean manufacturer, and distributor of medical devices for endoscopic and urologic procedures.  The deal is valued at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million. M.I.Tech offers HANAROSTENT technology, a…

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.09% on an annualized basis producing an average annual return of 20.41%. Currently, Boston Scientific has a market capitalization of $53.12 billion.

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.68% on an annualized basis producing an average annual return of 21.79%. Currently, Boston Scientific has a market capitalization of $58.91 billion.

Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) 

Boston Scientific Corp (NYSE:BSX) generated net sales of $3.026 billion in Q1 FY22, beating the Wall Street estimate of $2.95 billion. Sales increased 10% Y/Y on a reported basis, 12.6% on an operational basis, and 9.7% on an organic basis, better than the management estimate of approximately 5% - 8%. The Company achieved…